Lonza Group AG

Lonza Group AG’s 2025 earnings surge and Roche plant purchase spark a debate: strong revenue growth, but high debt, high P/E and risky global expansion challenge long‑term profitability.

Lonza Group AG shows resilient growth amid Swiss market swings, with a strong 37.8 billion CHF cap, high‑margin contracts, and 250%+ decade returns – a clear long‑term play for life‑science investors.

Lonza Group AG shares stay stable amid a steady Swiss market; the biotech firm’s biocatalyst focus and strong fundamentals suggest long‑term growth potential.

Lonza Group AG, a Swiss life sciences services provider, has acquired French company Redberry SAS, expanding its diagnostics portfolio and strengthening its presence in the European market.

Lonza Group AG demonstrates resilience and strategic foresight in the face of market volatility, positioning itself for future growth and innovation in the life sciences sector.

Lonza Group AG has reported a 29% increase in first-half profit, driven by its Contract Development and Manufacturing Organization (CDMO) business, and has raised its annual sales and margin outlook for 2025.

Lonza Group AG reported a strong first quarter for 2025, reaffirming its commitment to full-year targets despite market challenges, and positioning itself for continued growth and innovation in the life sciences sector.